Final results from a phase II trial of ZD1839 (“Iressa”) for patients with advanced non-small-cell lung cancer (IDEAL 1) [abstract 1188] - Fukuoka,M.; Yano,S.; Giaccone,G. (Proc Am Soc Clin Oncol, 2002)